Analysis links SERMs to breast cancer prevention benefit

05/1/2013 | MyHealthNewsDaily.com · PhysiciansBriefing.com

Taking selective estrogen receptor modulators such as tamoxifen and raloxifene after menopause reduces by 38% a woman's risk of developing any kind of breast cancer for 10 years, according to an analysis of data from nine studies. The estrogen-blocking drugs particularly lowered the risk of estrogen-receptor positive breast cancer, researchers found. The study appeared online in The Lancet.

View Full Article in:

MyHealthNewsDaily.com · PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA